Pfizer’s Talzenna snags broader prostate cancer nod than AstraZeneca and Merck’s rival PARP med – FiercePharma

by

  1. Pfizer’s Talzenna snags broader prostate cancer nod than AstraZeneca and Merck’s rival PARP med FiercePharma
  2. FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC OncLive
  3. Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval Yahoo Finance
  4. FDA Approves Talazoparib, Enzalutamide Combination for Metastatic Castration-Resistant Prostate Cancer Pharmacy Times
  5. FDA Approves Talzenna-Xtandi Combo for Subset of Patients With Prostate Cancer Curetoday.com
  6. View Full Coverage on Google News

Read original article here

Leave a Comment